New stem cell therapy may be fatal

By Peter Gorner
Tribune science reporter
Published June 4, 2002

Three years ago, Justin Sears was a carefree college student whose hands mysteriously started to shake when he tried to use his computer keyboard.

The tremors were sporadic at first, but grew increasingly severe. He tried to ignore what was happening to his hands, but he soon started having trouble with his balance. Before long, he couldn't even climb stairs.

He was diagnosed with multiple sclerosis (MS), a chronic, neurological disorder that affects 350,000 Americans and is characterized by damage to the nerves in the brain and spinal cord that becomes worse over time, leading to spasticity or paralysis of muscles.

But his disease seems to have been put on hold, thanks to a new and controversial stem cell therapy that he received at Northwestern Memorial Hospital.

Over the last 20 years, the transplantation of bone marrow stem cells revolutionized the treatment of leukemias and other cancers.

The revolution is gradually moving to autoimmune disorders such as multiple sclerosis, lupus, rheumatoid arthritis and Crohn's disease. But with that promise comes a cost: The stem cell therapy can be fatal, while MS rarely is.

Stem cells, the master cells that make blood, are retrieved from a patient's bloodstream before therapy and then returned to the same patient, a process known as autologous transplantation.

Although stem cells are found in larger numbers in bone marrow, removal from the bloodstream is easier, less costly and does not require general anesthesia. When re-infused into the bloodstream, they migrate into the bone marrow and--if the therapy is successful--produce a new immune system.

Such transplants demonstrate the regenerative behavior of stem cells--either from a stranger or from oneself--and their power to heal. They provide most of the hard evidence behind the stem cell revolution that has swept through science and is being debated in Congress and in countries worldwide.

Now 25, Sears, of the South Side, is back studying psychology at Moraine Valley Community College in Palos Hills. His symptoms have subsided. His future looks much brighter.

"I can write with a pen again," he said, ticking off the improvements. "The hand tremors are much better. I can butter my own bread and eat soup, which I couldn't do before. I can climb stairs again.

"Before, I couldn't walk a hundred feet. Now, I can walk for miles."

Nobody knows what causes MS, but it seems triggered when the body becomes allergic to itself and the misdirected immune system attacks the central nervous system--specifically, the myelin sheaths, the thin layers of fatty cells that wrap around and insulate nerve fibers of the brain and spinal cord.

Repeated attacks bring about a loss of the protective coating of myelin, which halts nerve cells from communicating much the way that frayed electrical wires short out and stop carrying current. MS is a crippler, not usually a killer, but the progression of the disease cannot be predicted and depends on the individual.

Northwestern Memorial has pioneered stem cell transplants for this and other devastating neurological disorders. Dr. Richard K. Burt, the hospital's director of immunotherapy, performed the first procedure in the U.S. in 1997. Based on the program's success so far, the National Institute of Allergy and Infectious Diseases awarded the hospital a $9.2 million contract for further research on stem cell transplants for autoimmune diseases.

Sears received his transplant in January 2001. After doctors removed stem cells from his own blood, they killed his immune system, which had turned into a renegade, and then returned the healthy bloodmaking cells to his body.

The cells set up shop and built a new immune system that didn't attack his myelin.

Sears was hospitalized for three weeks. The transplant cost $85,000, and Medicaid paid. If resetting the young man's immune system stops further damage from MS, the long-term costs of the disease would make stem cell transplants a bargain.

Sears' initial diagnosis, frightening as it was, was confounded even more because specialists could not predict what would happen to him.

Symptoms of MS may be mild--numbness or weakness in the limbs, blurred vision, clumsiness--or severe, such as paralysis, loss of intellect, blindness. About 70 percent of patients experience problems sporadically over several years--the "relapsing-remitting" form of the disease--but in others it progresses rapidly, leaving them bedridden, confined to a wheelchair or dead within 10 years.

Faced with such uncertainties, the MS research community is conservative and suspicious of any new therapy.

Studies of stem cell transplants for MS have involved small groups of severely disabled patients at research hospitals, and the evidence is mounting that the new treatment is safe. Trials are getting under way to test its efficacy and compare that to accepted treatments.

Researchers, like Northwestern's Burt, worry about raising false hopes.

"We recently completed our study of 29 patients, and in most of them the tests suggested no further loss of myelin," he said. "We seem to be holding the disease in check.

"On the other hand, despite the transplant, some of our more severely disabled patients continued to deteriorate. We may have stopped the further loss of myelin, but for them it didn't seem to matter.

"I think when people reach that point, there's something else going on. MS may actually be two diseases. When too many nerve cells have been destroyed, our stem cell therapy is like closing the barn door after the horse has left."

Doing the transplant earlier, though, brings a formidable ethical problem.

"We want to do this in people who are having acute attacks, before the long-term damage can accumulate," Burt said. "But this is a very dramatic, potential life-threatening therapy. And we'd be doing it on patients who otherwise might do well on ordinary treatment.

"Bone marrow transplants are ethical in cancer, which is a fatal disease. But MS rarely is fatal. So the ethics here are really tricky."

The Northwestern Memorial results fall in line with those reported by other institutions, where as many as 85 percent of transplanted MS patients seem to be doing better.

"Preventing people with MS from becoming disabled--that's the goal," Burt said. "No other therapy has done that. But it's still too early to say if stem cell transplants can prevent disability."

One of the first patients in the world to have the transplant before she was physically disabled was Air Force Capt. Deb Strand, a critical care nurse, who lives near Olympia, Wash.

"Because of MS, my life went to hell in a year and a half," she said. "I lost my job, my career, my nursing license--I had cognitive problems, started to stutter and couldn't remember patients. My IQ dropped from 130 in college to 87. I had to retire from the military."

She did research on the Internet, discovered Burt and came to Northwestern Memorial in July 2000. Her transplant was on Aug. 11--"that's when I celebrate my birthday," she said. "That's the day my new life began."

She still has problems, she admits.

"But nothing has progressed. Nothing has gotten worse. The transplant is not a cure-all; it's not like my MS has gone away. I still have short-term memory problems, but I can cope with them.

"I have stability in my life. I'm not in limbo-land any longer."

Doctors have known for 50 years that suppressing the immune system can slow the progression of MS, but the tradeoff could be fatal. Without a working immune system the body has nothing to fend off deadly bacteria or viruses.

The stem cell procedure has an unacceptable mortality rate--between 5 and 10 percent. But the rate in healthier patients has yet to be determined.

"It's in those people we want to reset the equilibrium," Burt said.

And Justin Sears, for one, couldn't agree more.

"The doctors told me not to count on the transplant reversing the disease," he said. "But I'm really glad I did it. So far, I love it. I absolutely love it."

Copyright © 2002, Chicago Tribune


 

 

 

Reversing Paralysis with Stem Cells

September  6, 2001

Bipedal Reptile
Image: Courtesy of David Anderson California Institute of Technology

Stem cells injected into the spinal fluid of newly paralyzed mice and rats can restore movement, according to a study described yesterday in New Orleans at the annual meeting of the Society for Neuroscience. Unlike most stem cell research, which has focused on repairing damage to small areas of the central nervous system (such as injuries caused by a stroke), this study is among the first to demonstrate the efficacy of stem cell treatment in restoring function over a large region of the central nervous system. Researchers say the new findings may lead to better treatments for human patients afflicted with motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal motor atrophy (SMA), which ultimately lead to paralysis and death.

Investigators led by neurologist Douglas Kerr of Johns Hopkins University injected neural stem cells (like those shown in the photograph) into the cerebrospinal fluid of 18 rodents infected with the Sindbis virus, which normally leads to permanent paralysis. Several weeks later the cells had migrated from the injection site at the based of the spinal cord up to the so-called ventral horn, a region that contains the bodies of motor nerve cells. "After eight weeks we saw definite functional improvement in half of the mice and rats," Kerr reports. "From 5 to 7 percent of the stem cells that migrated to the spinal cord appeared to differentiate into nerve cells."

Exactly how so few nerve cells can confer this considerable improvement in function is a question the team is working to explain. "It could be that fewer nerve cells are needed for function than we suspect," Kerr surmises. "The other explanation is that the stem cells themselves havenít restored the nerve-cell-to-muscle units required for movement but that, instead, they protect or stimulate the few undamaged nerve cells that still remain." Whatever the answer, the results do offer hope. "Under the best research circumstances," says team member Jeffrey Rothstein, "stem cells could be used in early clinical trials within two years." --Kate Wong

 Harvests Human Stem Cells

JULY 11, 02:19 EST 

Va. Lab Harvests Human Stem Cells          


 
Dr. William E. Gibbons
AP/Gary C. Knapp [19K]

  
NORFOLK, Va. (AP) ó Virginia scientists have become the first 
researchers to create human embryos in the lab for the sole purpose 
of harvesting their stem cells. 

Until now, scientists had derived stem cells only from excess embryos 
donated from infertility treatments. In this case, the scientists 
approached donors and informed them that their eggs and sperm would 
be used to develop embryos for stem-cell research. 

The work, conducted by researchers at the Jones Institute for 
Reproductive Medicine in Norfolk, drew criticism from religious 
conservatives opposed to embryo research. 

``I think this is a cautionary tale against starting down the 
slope,'' Richard Doerflinger of the National Conference of Catholic 
Bishops told The Washington Post in Wednesday's edition. 

``It's still killing a human being,'' Mary Petchel, president of the 
Tidewater chapter of the Virginia Society for Human Life, told The 
Virginian-Pilot of Norfolk, Va. 

Scientists who conducted the work said several review panels had 
assessed the ethical implications and concluded that the approach was 
at least as ethical as using spare frozen embryos. 

The group extracted eggs from 12 women, who signed consent documents 
and were paid $1,500 to $2,000 each, according to William Gibbons, a 
reproductive endocrinologist who was not involved in the work. 

Of the 162 eggs collected and inseminated by donor sperm, 50 embryos 
were successfully created. The researchers destroyed 40 of those to 
get the stem cells that resided inside. The work was done with 
private funds. 

The results appear in the July issue of the journal Fertility and 
Sterility, published Wednesday. The study began in 1997 and concluded 
last July. 

Interest in embryonic stem cells centers around their ability to 
generate other tissues of the body. Doctors hope using stem cells 
could possibly cure diseases as Alzheimer's, diabetes, cancer, 
Parkinson's, and spinal cord injuries. 

President Bush has said he will soon decide whether to allow taxpayer 
dollars to be used for research on embryonic stem cells. He is under 
pressure from patient groups that favor the research and opponents 
who feel the work is inherently unethical. 
Transplanted human stem cells develop into broad range of tissues

8 November 2000

Adult human stem cells taken from bone marrow have been induced to develop into a wide range of normal tissues, including bone, cartilage, fat, tendon and muscle, when transplanted into fetal sheep. The transplanted human cells have persisted in various sheep tissues for over one year without rejection by the sheepís immune system. The study offers promise that in the future these cells may be useful for tissue repair or regeneration and for treatment of degenerative diseases such as muscular dystrophy.
In the study reported in the November issue of Nature Medicine, researchers harvested mesenchymal stem cells (MSCs) from adult bone marrow. Although many institutions are currently investigating various types of stem cells, this is the first study examining transplantation of human MSCs in the fetal sheep model. In this current study, human MSCs were transplanted into fetal sheep early in gestation, at either 65 days or 85 days, before and after the brief window of time when their immune systems mature and become active.

 

 

                  

Other ways to help support our cause: sign up with igive.com through this link and they will donate $1.00 for every person who registers through us.

Veronica Davidson/ mommyv : founder and owner of Friends With MS.com.   If your interested in information about MS please  Email me!  Or you can check out our yahoo newsgroup and read all of our previous postings.  All web links are on the Home page!